Biogen Stock And The Limitation Of The Tau Approach To Alzheimer's Disease (NASDAQ:BIIB)

Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More " Biogen (BIIB) continues to work around the edges of Alzheimer's disease. Biogen's stock price did rise modestly after the U.S. Food and Drug Administration announced the approval of an injectable form of its anti-amyloid drug Leqembi. Shortly after this, Biogen Retired history instructor. Alzheimer's disease researcher for the past two decades.My goal is to give investors solid advice based on the mechanisms of action of Alzheimer's drugs. This advice is informed by a background in biology (conservation, ecology, evolution, environmental science, and biochemistry) and twenty years of a very in depth review of the research on Alzheimer's disease. I have come to the conclusion that Alzheimer's disease is caused by oxidation and nitration. Many treatments for Alzheimer's disease address factors that can contribute to oxidation and nitration such as misfolded amyloid and tau proteins and neuroinflammation, but very few direct scavenge compounds (such as hydrogen peroxide and peroxynitrite) that cause oxidation and nitration nor do they reverse any of the damage already present. Thus, most treatments for Alzheimer's disease only slow down the early progression of the disease for awhile. Certain natural products such as panax ginseng and various essential oils via aromatherapy inhibit oxidation and nitration, scavenge agents that cause oxidative and nitrostative stress, and reverse part of their damage. Such treatments have the potential to stabilize Alzheimer's disease. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Biogen Stock And The Limitation Of The Tau Approach To Alzheimer's Disease (NASDAQ:BIIB) | Seeking Alpha

Інші новини компанії